Filing Details
- Accession Number:
- 0001415889-23-001757
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-01 21:50:12
- Reporting Period:
- 2023-01-30
- Accepted Time:
- 2023-02-01 21:50:12
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1604821 | Natera Inc. | NTRA | Services-Medical Laboratories (8071) | 010894487 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1697362 | Burkes Michael Brophy | C/O Natera, Inc. 13011 Mccallen Pass Building A Suite 100 Austin TX 78753 | Chief Financial Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-01-30 | 47,188 | $42.05 | 105,499 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-01-30 | 1,509 | $43.14 | 103,990 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-01-31 | 35,000 | $42.33 | 68,990 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-02-01 | 4,761 | $42.81 | 64,229 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-02-01 | 10,413 | $43.81 | 53,816 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-02-01 | 4,152 | $44.35 | 49,664 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2022.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.0396 to $42.1307 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.3323 to $42.3275 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.24 to $43.22 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.24 to $44.23 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.24 to $44.59 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.